Filing Details

Accession Number:
0001144204-17-032552
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-06-14 16:50:20
Reporting Period:
2017-06-14
Filing Date:
2017-06-14
Accepted Time:
2017-06-14 16:50:20
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1372514 Eyegate Pharmaceuticals Inc EYEG Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1620137 Stephen From C/O Eyegate Pharmaceuticals, Inc.
271 Waverley Oaks Road, Suite 108
Waltham MA 02452
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-06-14 60,000 $0.00 259,965 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Warrants (right to buy) Acquisiton 2017-06-14 60,000 $0.00 60,000 $1.50
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
60,000 2017-06-14 2022-06-14 No 4 P Direct
Footnotes
  1. The reported securities were purchased by the reporting person for a combined purchase price of $1.50 per share of common stock and warrant in connection with the Issuer's public offering that closed on June 14, 2017. Each warrant will be exercisable during the period commencing on June 14, 2017 and ending on June 14, 2022 at an exercise price of $1.50.